Get the Daily Brief
Latest Biotech News
Plant Growth and Environmental Adaptation Mechanisms Unveiled
Plant biologists have decoded cellular mechanisms that regulate growth and adaptability to changing environments. At the University of Freiburg, researchers identified a molecular growth switch...
Biotech Industry Leadership Changes and Financial Moves Update the Sector Landscape
September 2025 has seen notable leadership appointments and financing activities within the biotech and med-tech sectors. CatalYm appointed Clinton Musil as CFO and chief business officer as it...
Pfizer Accelerates Obesity Portfolio With $4.9B Metsera Deal
Pfizer has struck a deal to acquire Metsera, a biotech focused on obesity and cardiometabolic therapeutics, for $4.9 billion upfront with additional milestone payments potentially raising the...
Roche Sets Ambitious Obesity Goals With New Pipeline and Strategy
Roche outlined plans to become a 'top three' player in the obesity treatment market by 2030, leveraging multiple pipeline assets including acquired candidates from Carmot Therapeutics and...
FDA Approves Merck’s Injectable Keytruda for Faster Cancer Treatment
The FDA has approved an injectable formulation of Merck’s cancer immunotherapy Keytruda (Qlex), reducing administration time to minutes compared to the conventional infusion which takes around 30...
Ionis Pharmaceuticals Eyes FDA Filing After Rare Neurological Disease Trial Success
Ionis Pharmaceuticals reported positive Phase 3 trial data for its antisense oligonucleotide targeting mobility stabilization in Alexander disease, a rare and often fatal neurological disorder....
OGT Secures FDA Authorization for Companion Diagnostic in Acute Leukemia
British genomics firm OGT received FDA de novo clearance for its CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for Syndax Pharmaceuticals’ Revuforj (revumenib). The assay...
MapLight Therapeutics Files IPO to Challenge Bristol Myers in Neuropsychiatric Drugs
MapLight Therapeutics, developing drugs targeting muscarinic receptors for schizophrenia and Alzheimer's psychosis, filed for an IPO aiming to compete with Bristol Myers Squibb’s recently approved...
Stealth BioTherapeutics Wins FDA Approval for Barth Syndrome Drug After Delay
Stealth BioTherapeutics received accelerated FDA approval for elamipretide, a treatment for Barth syndrome, a rare mitochondrial disease, resolving a protracted regulatory process that had...
Capsida Bio Halts Gene Therapy Trial After Pediatric Patient Death
Capsida Bio has suspended its SYNRGY trial of CAP-002, an AAV-based gene therapy for rare STXBP1 encephalopathy, following the death of the first treated child patient. The affected disease causes...
Dana-Farber Develops AI-Driven Diagnostic Tool Revolutionizing Acute Leukemia
Researchers at Dana-Farber Cancer Institute introduced MARLIN, an innovative diagnostic technology combining DNA methylation profiling with machine learning to rapidly classify acute leukemia...
Phase Scientific Launches Large-Scale Urine-Based HPV Test Study in China
Phase Scientific initiated a prospective clinical study in China to assess the effectiveness of its urine-based human papillomavirus (HPV) DNA test for cervical cancer screening, targeting up to...
Pfizer Accelerates Obesity Pipeline with $4.9 Billion Metsera Acquisition
Pfizer has announced a definitive $4.9 billion cash acquisition of Metsera, a biotech focused on experimental injectable and oral obesity drugs. The deal, which includes contingent value rights...
Roche Sets Ambitious Goal to Become Top 3 Obesity Pharma by 2030
Roche unveiled a comprehensive strategy to become a top three player in the obesity market by 2030. CEO Teresa Graham emphasized the company’s robust pipeline, commercial capabilities, and...
Merck Wins FDA Nod for Injectable Keytruda: Faster Cancer Immunotherapy Delivery
Merck received FDA approval for Keytruda Qlex, an injectable form of its blockbuster cancer immunotherapy Keytruda. The new formulation allows dosing in minutes, compared to 30 minutes with the...
OGT Scores FDA Clearance for Companion Diagnostic in Acute Leukemia
British genomics company OGT secured FDA de novo authorization for its CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s Revuforj (revumenib) in relapsed or...
Capsida Bio Halts STXBP1 Gene Therapy Trial After Patient Death
Capsida BioTherapeutics announced a voluntary hold on its SYNRGY Phase I/IIa clinical trial following the death of the first treated pediatric patient with STXBP1-related disorders, a rare...
MBX Biosciences Posts Positive Phase 2 Data in Hypoparathyroidism
MBX Biosciences reported that its once-weekly investigational hormone replacement drug canvuparatide achieved a 63% response rate in a Phase 2 trial for chronic hypoparathyroidism, outperforming...
Breakthrough Small Molecule Stabilizer May Treat Majority of Rare Disease Mutations
Researchers at the Centre for Genomic Regulation and Wellcome Sanger Institute published evidence that a single, FDA-approved small molecule drug can stabilize nearly all missense variants of the...
Genfit Terminates Acute Liver Failure Program After Serious Adverse Event
Genfit has discontinued development of its lead asset VS-01 in acute-on-chronic liver failure (ACLF) after a patient experienced peritonitis during a Phase 2 trial. The decision follows a data...